JPH0358718B2 - - Google Patents
Info
- Publication number
- JPH0358718B2 JPH0358718B2 JP3342383A JP3342383A JPH0358718B2 JP H0358718 B2 JPH0358718 B2 JP H0358718B2 JP 3342383 A JP3342383 A JP 3342383A JP 3342383 A JP3342383 A JP 3342383A JP H0358718 B2 JPH0358718 B2 JP H0358718B2
- Authority
- JP
- Japan
- Prior art keywords
- cpp
- casein
- trypsin
- ferric
- precipitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 23
- 235000021240 caseins Nutrition 0.000 claims description 23
- 239000005018 casein Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- 102000004142 Trypsin Human genes 0.000 claims description 13
- 108090000631 Trypsin Proteins 0.000 claims description 13
- 239000012588 trypsin Substances 0.000 claims description 13
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 8
- 229910001447 ferric ion Inorganic materials 0.000 claims description 7
- 108010001441 Phosphopeptides Proteins 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000000354 decomposition reaction Methods 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 102000011632 Caseins Human genes 0.000 description 26
- 108010076119 Caseins Proteins 0.000 description 26
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 229910021645 metal ion Inorganic materials 0.000 description 7
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000021247 β-casein Nutrition 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- -1 milk Chemical compound 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- GLMQHZPGHAPYIO-UHFFFAOYSA-L azanium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [NH4+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O GLMQHZPGHAPYIO-UHFFFAOYSA-L 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
本発明は、カルシウムの吸収促進作用を有する
カゼインホスホペプチド(Casein
Phosphopeptide以下CPPと略記する)の精製法
に関する。詳しくは、カゼインのトリプシンで加
水分解して生成したCPPを金属イオン特に、第
2鉄イオンを用い、高純度に精製する方法に関す
る。
CPPはカルシウム吸収促進因子として最近そ
の性質が用らかにされてきた物質である〔内藤
博、化学と生物18 551〜558(1980)、Y.S.Lee,
T.Noguchi and H.Naito,British Journal of
Nutrition 43 457〜467(1980)〕。牛乳は古くか
らその栄養の完全さで知られ、その多くの効果の
うちカルシウムの供給源としてあらゆる食品の中
で最も優れたものとされているが、その因子とし
てCPPは重要なものである。このCPPには代表
的な2種が存在していることが知られている。す
なわち、β−カゼイン由来のもの(β−CPPと
略記)とα−カゼイン由来のもの(α−CPPと
略記)の2種で、その構造及び恒数は次の表1に
示した通りである。特にβ−CPPは良く研究さ
れ構造も決定されている。〔W.Manson,W.D.
Annan;Archives of Biochemistry and
Biochemistry 145 16〜26頁(1971)〕
しかし、α−CPPについては推定構造で更に
分解の進んだものも考えられる。
The present invention provides casein phosphopeptides (casein phosphopeptides) that have a calcium absorption promoting effect.
This invention relates to a method for purifying phosphopeptide (hereinafter abbreviated as CPP). Specifically, the present invention relates to a method for purifying CPP produced by hydrolyzing casein with trypsin to a high purity using metal ions, particularly ferric ions. CPP is a substance whose properties have recently been revealed as a calcium absorption promoting factor [Hiroshi Naito, Chemistry and Biology 18 551-558 (1980), YSLee,
T.Noguchi and H.Naito, British Journal of
Nutrition 43 457-467 (1980)]. Milk has long been known for its nutritional integrity, and among its many benefits, it is considered the best source of calcium among all foods, and CPP is an important factor. It is known that there are two representative types of CPP. That is, there are two types, one derived from β-casein (abbreviated as β-CPP) and one derived from α-casein (abbreviated as α-CPP), and their structures and constants are as shown in Table 1 below. . In particular, β-CPP has been well studied and its structure has been determined. [W. Manson, W.D.
Annan;Archives of Biochemistry and
Biochemistry 145 pp. 16-26 (1971)] However, it is conceivable that α-CPP has a further decomposed structure in its presumed structure.
【表】【table】
【表】
本表におけるアミノ酸残基の略号の
Ala:L−アラニン、Arg:L−アルギニン、
Asp:L−アスパラギン酸、Asn:L−アスパラ
ギン、Glu:L−グルタミン酸、Gln:L−グル
タミン、Gly:グリシン、Ile:L−イソロイシ
ン、Leu:L−ロイシン、Lys:L−リジン、
Met:L−メチオニン、Pro:L−プロリン
Ser:L−セリン
Ser:L−ホスホセリン
Thr:L−スレオニン、Val:L−バリン、
H2N・Asp:N末端L−アスパラギン酸、
H2N・Arg:N末端L−アルギニン、
Lys・COOH:c未端L−リジン、Arg・
COOH:c未端L−アルギニンをそれぞれ示す
ものである。
CPPの調製方法としては以下に示す方法が知
られている。
結晶トリプシンでβ−カゼインを加水分解
し、CPPを生成させた後、PH4.7で未反応カゼ
インと一部の不純物を沈澱除去した後上清部に
塩化バリウムとエタノール(終濃度50%(v/
v))を加えてCPPを沈澱として回収する方法
〔例えばR.F.Peterson,L.W.Nouman and T.
L.McMeekin,Journal of the American
Chemical Society 80 95〜99(1958)〕
結晶トリプシンでβ−カゼインを加水分解
し、CPPを生成させた後、トリクロル酢酸で
処理し、不溶物を除去後水酸化ナトリウムによ
り中和(PH5.0)する。その後、ゲル濾過カラ
ム(Sephadex G−25
Pharmacia社)に
より粗分画し、更にイオン交換樹脂カラム
(Dowex×50×2
Dow Chemical Co.)に
一たん吸着させピリジン−酢酸緩衝液(0.2規
定PH2.5)で溶出し精製する方法〔H.Naito
and H.Suzuki,Agricultural Biological
Chemistry 38 1543〜1545(1974)〕
,の方法ともβ−カゼインを使用してお
り、この場合には、予めカゼインからβ−カゼイ
ンを精製する必要があり、収率の低下をもたらし
不利である。又ではバリウム塩、ではトリク
ロル酢酸、ピリジンを使用しており、これらを使
用したものは到底飲食に供することができない。
またに於てはカラムでのCPPの処理量は少少
量で工業的製造には適用し難い。
本出願人が先に出願した特願昭57−52639号
(特開昭58−170440号)(昭和57年3月30日出願)
に於ては、基本的にはの方法を用いているが、
カゼインを原料として用いて、塩化バリウムの代
りにカルシウム塩に変えて、CPPを回収し、そ
のまま飲食に供せるようにしたものであるが、エ
タノール等の有機溶媒を大量に使用する点で、工
業的には不利である。
本発明者らは、このCPPの精製法について鋭
意検討を重ねた結果、CPPが各種金属イオンと
相互作用を有することを見出した。更にある種の
金属イオン、特に第2鉄イオンにより有機溶媒を
全く使用することなしに、CPPを高純度に回収
できることを見出し、本発明を完成させた。
本発明によれば、カゼインをトリプシンで加水
分解し、CPPを生成させた後に金属イオンを添
加し、CPPを沈澱させ回収するので、操作は簡
単であり、且つ有機溶媒を全く使用しないので、
工業的には極めて有利である。
次に本発明の方法について説明する。この方法
はカゼインにトリプシン又はトリプシンを含む酵
素剤を作用させ、CPPを含む分解物溶液を調製
し、これに第2鉄イオンを添加してCPPを回収
する方法である。
本製造に使用する原料であるカゼインは、各種
酸カゼイン、カゼインナトリウム、カゼインカル
シウム等のカゼインが最も良いが、牛乳、スキム
ミルク等の未精製のものでも原料として用いるこ
とができる。本製法に従えば、この原料カゼイン
を水に溶解し、トリプシン又はトリプシンを含む
酵素剤を加える。本発明に使用するトリプシン又
はそれを含む酵素剤としては、市販の膵臓性の酵
素(パンクレアチン)でも十分であるが、収率等
の点から、結晶グレードのものが好ましい。
原料のカゼインに上記酵素を作用させることに
よつて、両者が反応してCPPを生成する。この
際、工業的酵素反応条件は、反応時のカゼイン濃
度は30以下、好ましくは2〜30%、反応PHは6.0
〜9.0、反応温度は15〜60℃、好ましくは20〜50
℃が良好にCPPが生成し好都合である。
酵素使用量は対基質カゼイン重量に対し、結晶
トリプシンとして0.001%〜2%相当の量で、処
理時間は5分〜100時間で十分反応が進行しCPP
を生成することができる。
以上の如くして生成したCPPを回収するには、
第2鉄イオンを添加することにより実施される。
表2に各種金属イオンで試験した結果を示す。表
2からわかるようにエタノール存在下では、バリ
ウムをはじめとして多くの金属イオンによつて
CPPを沈澱させることが可能であるが、発明者
らは、エタノールなしに金属イオンのみでCPP
を沈澱回収する方法を検討し、塩化第2鉄、塩化
亜鉛、酢酸鉛、酢酸ウラニウムによつてCPPを
沈澱として精製できることを見出した。CPPは
通常、食品として摂取することから考えて、第2
鉄(Fe+++)イオンが好適と考えられる。
次に第2鉄イオンの給源について、さらに詳細
に検索したところ、表3の結果を得た。表3から
明らかなように第2鉄塩のうち、ピロリン酸第2
鉄のように水に不溶性の塩や、クエン酸鉄アンモ
ニウムのように錯塩を形成している第2鉄塩は、
本精製には不向きで、遊離型の第2鉄イオンを生
ずるものが好ましいことがわかつた。又硫酸第1
鉄のように本来単独ではCPPの沈澱が生じない
ものでも、空気酸化等により第2鉄に変化させる
と、CPPの沈澱が生ずることも判明した。[Table] Abbreviations of amino acid residues in this table: Ala: L-alanine, Arg: L-arginine,
Asp: L-aspartic acid, Asn: L-asparagine, Glu: L-glutamic acid, Gln: L-glutamine, Gly: glycine, Ile: L-isoleucine, Leu: L-leucine, Lys: L-lysine,
Met: L-methionine, Pro: L-proline Ser: L-serine Ser: L-phosphoserine Thr: L-threonine, Val: L-valine,
H 2 N・Asp: N-terminal L-aspartic acid,
H 2 N・Arg: N-terminal L-arginine, Lys・COOH: c-terminal L-lysine, Arg・
COOH: c-terminal L-arginine. The following methods are known as methods for preparing CPP. After hydrolyzing β-casein with crystalline trypsin to generate CPP, unreacted casein and some impurities were removed by precipitation at pH 4.7, and the supernatant was mixed with barium chloride and ethanol (final concentration 50% (v). /
v))) to recover CPP as a precipitate [for example, RF Peterson, LW Nouman and T.
L. McMeekin, Journal of the American
Chemical Society 80 95-99 (1958)] Hydrolyze β-casein with crystalline trypsin to generate CPP, then treat with trichloroacetic acid, remove insoluble materials, and neutralize with sodium hydroxide (PH5.0) do. After that, it was crudely fractionated using a gel filtration column (Sephadex G-25 Pharmacia), and then adsorbed onto an ion exchange resin column (Dowex x 50 x 2 Dow Chemical Co.) and then added to a pyridine-acetate buffer (0.2N PH2). 5) Elution and purification method [H.Naito
and H.Suzuki, Agricultural Biology
Chemistry 38 1543-1545 (1974)] also uses β-casein, and in this case, it is necessary to purify β-casein from casein in advance, which is disadvantageous as it results in a decrease in yield. In addition, barium salt uses trichloroacetic acid and pyridine, and products using these cannot be used for consumption.
In addition, the amount of CPP processed in the column is small, making it difficult to apply it to industrial production. Patent Application No. 57-52639 (Japanese Unexamined Patent Publication No. 170440-1981) previously filed by the applicant (filed on March 30, 1982)
Basically, we use the method of
This method uses casein as a raw material and replaces barium chloride with calcium salt, allowing CPP to be recovered and used for consumption as is. This is disadvantageous. The present inventors have conducted extensive studies on the method for purifying CPP, and as a result, have found that CPP interacts with various metal ions. Furthermore, they discovered that CPP can be recovered with high purity using certain metal ions, particularly ferric ions, without using any organic solvents, thereby completing the present invention. According to the present invention, casein is hydrolyzed with trypsin to generate CPP, and then metal ions are added to precipitate and recover CPP, so the operation is simple and no organic solvent is used.
It is extremely advantageous industrially. Next, the method of the present invention will be explained. In this method, trypsin or an enzyme containing trypsin is applied to casein to prepare a decomposition product solution containing CPP, and ferric ions are added to this to recover CPP. Casein, which is a raw material used in this production, is best casein such as various acid caseins, sodium caseinate, calcium casein, etc., but unpurified casein such as milk, skim milk, etc. can also be used as a raw material. According to this production method, this raw material casein is dissolved in water, and trypsin or an enzyme agent containing trypsin is added. Although a commercially available pancreatic enzyme (pancreatin) may be sufficient as trypsin or an enzyme agent containing trypsin used in the present invention, crystal grade enzymes are preferred from the viewpoint of yield and the like. By allowing the above-mentioned enzyme to act on the raw material casein, the two react to produce CPP. At this time, the industrial enzyme reaction conditions are that the casein concentration during the reaction is 30 or less, preferably 2 to 30%, and the reaction pH is 6.0.
~9.0, reaction temperature is 15-60℃, preferably 20-50℃
℃ is convenient because CPP is generated well. The amount of enzyme used is equivalent to 0.001% to 2% of crystal trypsin based on the weight of casein as a substrate, and the reaction time is 5 minutes to 100 hours, and the reaction progresses sufficiently to produce CPP.
can be generated. To recover the CPP generated as above,
This is done by adding ferric ions.
Table 2 shows the results of tests with various metal ions. As can be seen from Table 2, in the presence of ethanol, many metal ions including barium
Although it is possible to precipitate CPP, the inventors have shown that CPP can be precipitated with only metal ions without ethanol.
We investigated a method for precipitating and recovering CPP, and found that CPP could be purified as a precipitate using ferric chloride, zinc chloride, lead acetate, and uranium acetate. Considering that CPP is usually ingested as food, the second
Iron (Fe +++ ) ions are considered suitable. Next, a more detailed search was conducted regarding the source of ferric ions, and the results shown in Table 3 were obtained. As is clear from Table 3, among ferric salts, pyrophosphate
Salts that are insoluble in water, such as iron, and ferric salts that form complex salts, such as iron ammonium citrate, are
It was found that those which are unsuitable for main purification and produce free ferric ions are preferable. Also, sulfuric acid No. 1
It has also been found that even in substances such as iron, which do not cause CPP precipitation when used alone, CPP precipitation occurs when it is converted to ferric iron by air oxidation or the like.
【表】
るように添加
[Table] Add as shown
【表】【table】
【表】
で分析した。
塩化第2鉄の濃度が5mM以上でCPPは沈澱を
生じ、塩化第2鉄の濃度が増加するにつれ、
CPP沈澱回収率は増加する。しかし逆にCPPの
純度は次第に低下する。商品としては、50%以上
のCPPが好ましいので、添加する塩化第2鉄の
濃度は5〜50mMが好ましい。
以上の方法により得られたCPP沈澱の採取は
一般に使用されている方法、例えば、デカンテー
シヨン、濾過、遠心分離などにより実施される。
得られたCPPの沈澱を、少量の水、アルコール
等で洗浄することにより更に純度を向上させるこ
ともできる。
以上の如くして回収されたCPPの沈澱は、通
常実施される乾燥方法、例えば熱風乾燥、流動層
乾燥、真空乾燥等の方法で実施し、淡黄〜黄褐
色、殆ど無臭、無味の粉末が得られる。
以上の如くして得られたCPPの純度の分析は
含まれる窒素の含量をケルダール法によつて定量
し、リンの含量をアレン(Allen)の湿式灰化法
と中村変法により定量し、両者の原子数比(N/
P比)を算出することによつて分析する。
本発明の方法により得られるCPPはN/P比
7〜20のものであり、カゼイン分解物特有の苦味
も実質上殆ど無視でき、そのまま飲食に用いるこ
とができる。また、CPP中には芳香族アミノ酸
が含まれていない。従つて、それに起因する紫外
部吸収(例えば280nm、254nm)が殆どなく、ペ
プチド結合由来の吸収(205〜220nm)しか認め
られない。
このCPPの別の分析法として高速液体クロマ
ト装置による分析も可能である。例えばTSK−
GEL、G−2000SW(東洋曹達製)のカラムを用
い、PH6.5、0.1Mリン酸緩衝液(0.1M塩化ナトリ
ウムを含む)の溶媒系で行うこともできる。検出
は例えば215nmの紫外部吸収で行う。この方法に
より分析したところ、本発明により得られた
CPPはα−CPP由来と推定される成分とβ−
CPP由来と推定される成分と両方含んでおり、
CPPの含有量は50%以上である。
次に本発明の方法を実施例で説明する。
実施例 1
乳酸カゼイン(ニユージーランド産)10gを水
に溶解し10%溶液とした(PH8.0)。この溶液に豚
の結晶トリプシン(ノボ社製)を対基質0.01%添
加しPH7.5〜8.5で50℃、6時間反応させた。この
反応液に、塩化第2鉄を10mMの濃度になるよう
に添加し撹拌後、5℃で一夜放置した。沈澱とな
つたCPP画分を遠心分離によつて回収し、少量
の水で洗浄した。その後真空乾燥し、CPP画分
1.2gを得た。CPP純度は92%、N/P=8.9であ
つた。Analyzed in [Table].
CPP precipitates when the concentration of ferric chloride is above 5mM, and as the concentration of ferric chloride increases,
CPP precipitation recovery rate increases. However, conversely, the purity of CPP gradually decreases. As a commercial product, CPP of 50% or more is preferable, so the concentration of ferric chloride added is preferably 5 to 50 mM. The CPP precipitate obtained by the above method is collected by commonly used methods such as decantation, filtration, and centrifugation.
The purity can be further improved by washing the obtained CPP precipitate with a small amount of water, alcohol, etc. The CPP recovered as described above is precipitated by a commonly used drying method, such as hot air drying, fluidized bed drying, vacuum drying, etc., to form a light yellow to yellowish brown, almost odorless and tasteless powder. can get. The purity of the CPP obtained as described above was analyzed by quantifying the nitrogen content by the Kjeldahl method, and the phosphorus content by Allen's wet ashing method and Nakamura's modified method. Atomic ratio (N/
P ratio). The CPP obtained by the method of the present invention has an N/P ratio of 7 to 20, and the bitterness characteristic of casein decomposition products can be virtually ignored, and it can be used as is for food and drink. Furthermore, CPP does not contain aromatic amino acids. Therefore, there is almost no ultraviolet absorption (for example, 280 nm, 254 nm) caused by this, and only absorption derived from the peptide bond (205 to 220 nm) is observed. Another analysis method for this CPP is analysis using a high performance liquid chromatography device. For example, TSK−
It can also be carried out using a column of GEL, G-2000SW (manufactured by Toyo Soda) in a solvent system of PH6.5 and 0.1M phosphate buffer (containing 0.1M sodium chloride). Detection is performed, for example, by ultraviolet absorption at 215 nm. When analyzed by this method, it was found that the
CPP is a component estimated to be derived from α-CPP and β-
Contains both components presumed to be derived from CPP,
The content of CPP is more than 50%. Next, the method of the present invention will be explained with examples. Example 1 10 g of lactic acid casein (produced in New Zealand) was dissolved in water to make a 10% solution (PH8.0). Porcine crystal trypsin (manufactured by Novo) was added to this solution at 0.01% relative to the substrate, and the mixture was reacted at 50° C. for 6 hours at pH 7.5 to 8.5. To this reaction solution, ferric chloride was added to a concentration of 10 mM, and after stirring, the mixture was left at 5° C. overnight. The precipitated CPP fraction was collected by centrifugation and washed with a small amount of water. Afterwards, vacuum dry and CPP fraction
1.2g was obtained. CPP purity was 92%, N/P = 8.9.
Claims (1)
ンホスホペプチドを生成させた後、その分解液に
第2鉄イオンを加えカゼインホスホペプチドを沈
澱として回収することを特徴とするカゼインホス
ホペプチドの精製法。1. A method for purifying casein phosphopeptides, which comprises hydrolyzing casein with trypsin to generate casein phosphopeptides, and then adding ferric ions to the decomposition solution to recover the casein phosphopeptides as a precipitate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3342383A JPS59159793A (en) | 1983-02-28 | 1983-02-28 | Purification of casein phosphopeptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3342383A JPS59159793A (en) | 1983-02-28 | 1983-02-28 | Purification of casein phosphopeptide |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS59159793A JPS59159793A (en) | 1984-09-10 |
JPH0358718B2 true JPH0358718B2 (en) | 1991-09-06 |
Family
ID=12386148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3342383A Granted JPS59159793A (en) | 1983-02-28 | 1983-02-28 | Purification of casein phosphopeptide |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59159793A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2650955B1 (en) * | 1989-08-16 | 1992-01-10 | Agronomique Inst Nat Rech | PROCESS FOR OBTAINING, FROM THE BETA CASE, ENRICHED FRACTIONS IN BIOLOGICALLY ACTIVE PEPTIDES AND THE PEPTIDE FRACTIONS OBTAINED |
JPH0724597B2 (en) * | 1990-02-22 | 1995-03-22 | 明治乳業株式会社 | Method for separating and concentrating phosphopeptides |
US5290685A (en) * | 1990-02-22 | 1994-03-01 | Meiji Milk Products Company Limited | Method for separation and concentration of phosphopeptides |
-
1983
- 1983-02-28 JP JP3342383A patent/JPS59159793A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS59159793A (en) | 1984-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5276138A (en) | Process for solubilizing animal hair | |
EP0034083B1 (en) | Process for the treatment of a material based on casein containing phosphocaseinates of monovalent cations or their derivatives, products obtained and applications | |
McDonagh et al. | Production of caseinophosphopeptides (CPPs) from sodium caseinate using a range of commercial protease preparations | |
WO1994012053A1 (en) | Low-phosphorus whey protein, process for producing the same, hydrolyzate of purified low-phosphorus whey protein, and process for producing the same | |
JPH027616B2 (en) | ||
WO2006101301A1 (en) | Calcium binding amino acid | |
JPS5854786B2 (en) | Method for producing protein hydrolyzate from whey protein | |
WO2004104036A1 (en) | Process for producing soyeban whey protein and digested soybean whey protein | |
JPH0358718B2 (en) | ||
JP3234222B2 (en) | Formation of phosphopeptides from casein | |
Kase et al. | Hydrolysis of neo-kyotorphin (Thr-Ser-Lys-Tyr-Arg) and [Met] enkephalin-Arg6-Phe7 by angiotensin-converting enzyme from monkey brain | |
JPH04341193A (en) | Production of peptide or its salt | |
JPS59159792A (en) | Production casein phosphopeptide | |
CN112898172A (en) | Synthesis method of amphiphilic functional group compound capable of being enzymolyzed by carboxypeptidase | |
JP2785956B2 (en) | Peptide mixture | |
JPWO2004104027A1 (en) | Angiotensin converting enzyme inhibitory peptide-containing composition | |
AU642530B2 (en) | A process for treating animal hairs by means of solubilization | |
JPH0379979B2 (en) | ||
JPS6357598A (en) | Quaternary trimethylammonium-derived casein polypeptide | |
JPH07227217A (en) | Highly water-soluble soybean protein | |
JP3437129B2 (en) | Mineral binding peptide derived from egg yolk phosphoprotein | |
JPH03236791A (en) | Production of phosphopeptide-containing new material | |
JPS5856613B2 (en) | Method for producing phosphorylated soy protein | |
JPS63216437A (en) | Production of hydrolyzed gluten | |
JPH02234642A (en) | Low-molecular peptide composition and production thereof |